Ruxolitinib cream for Atopic Dermatitis

"This medical study is no longer accepting participants, having first been posted on December 16th 2021 and last updated July 29 2022. Should you be seeking other studies related to eczema or infantile conditions, there are currently 235 trials for the former and 97 for Ruxolitinib cream actively recruiting patients."

"Ruxolitinib cream was first used in a study conducted at National Institutes of Health Clinical Center, 9000 Rockville Pike back in 2002. Since then, 91 trials have been completed and the current slate consists of 97 active ones with many based out of Gresham Oregon."

"Volunteers can join this trial in 16 different locations, such as Cyn3Rgy Research - Clinedge - Ppds based in Gresham, Orange County Research Center located in Anaheim and San Marcus Research Clinic Inc. established at Miami Lakes."

"Following the eligibility requirements of this research, children aged two to eleven are suitable for recruitment."

"Due to its Phase 1 status, there is limited evidence surrounding the safety and efficacy of Ruxolitinib cream. Our team at Power assigned it a score of 1 on our scale from one to three."

"This clinical trial has closed its recruitment phase; it was first posted on December 16th 2021 and the site's most recent update occured on July 29th 2022. However, there are currently 235 trials actively enrolling patients with eczema symptoms and 97 studies for Ruxolitinib cream searching for participants to join."

"Ruxolitinib cream is a commonly prescribed remedy for polycythemia vera, as well as hydroxyurea-resistant or -intolerant primary myelofibrosis and other forms of polycythemia."

"This study has 29 openings for children aged between two and eleven who are afflicted with eczema. To be considered, they must meet the following criteria: male or female 2-11 year old (age at time of screening), an active condition persisting for three months prior to enrollment in the trial, a score of 4+ on Itch NRS during screening period if 6-11 years old; 35% severity rating based on EASI scale at both baseline and screening visits; target lesion that measures ≥5 cm2 located anywhere except face, hands, feet or genitalia; discontinue all other treatments used for AD from start"